Fibroblast Activation Protein-Targeted PET/CT Imaging in a Treatment-Naive Prostate Cancer Patient With Low PSMA Expression

Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004825. Online ahead of print.ABSTRACTProstate-specific membrane antigen (PSMA) PET/CT has become increasingly accepted for imaging prostate cancer (PCa), including its recent use in primary staging. In this case report, we present the case of a 76-year-old man with newly diagnosed PCa. 18F-PSMA-1007 PET/CT showed minimal PSMA activity in the primary tumor and metastases. However, 18F-FAPI-04 PET/CT revealed more avid lesions in primary tumor, metastatic lymph nodes, and bones. Subsequent histopathologic examination confirmed the diagnosis of PCa. These findings suggest that 18F-FAPI-04 may have a potential role in the evaluation of PCa with low PSMA expression in treatment-naive patients.PMID:37703425 | DOI:10.1097/RLU.0000000000004825
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research